So How Is AI Drug Discovery Doing, Really?
Summary
The article's body discusses designer receptors activated by designer drugs (DREADDs) and chemogenetic therapies in neuroscience, including seven clinical trials in China and safety concerns with viral vectors. It notes potential to avoid surgical interventions, but highlights immune reactions and regulatory hurdles. The title suggests AI drug discovery, but the actual text focuses on biotech therapies and translational challenges.